Breakeven Is Near for Ocumension Therapeutics (HKG:1477)

Ocumension Therapeutics (HKG:1477) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The HK$6.6b market-cap company posted a loss in its most recent financial year of CN¥268m and a latest trailing-twelve-month loss of CN¥249m shrinking the gap between loss and breakeven. The most pressing concern for investors is Ocumension Therapeutics' path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Ocumension Therapeutics is bordering on breakeven, according to the 2 Hong Kong Pharmaceuticals analysts. They expect the company to post a final loss in 2025, before turning a profit of CN¥68m in 2026. So, the company is predicted to breakeven approximately a year from now or less! At what rate will the company have to grow in order to realise the consensus estimates forecasting breakeven in under 12 months? Using a line of best fit, we calculated an average annual growth rate of 115%, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.

Given this is a high-level overview, we won’t go into details of Ocumension Therapeutics' upcoming projects, though, keep in mind that typically pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Check out our latest analysis for Ocumension Therapeutics

Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital prudently, with debt making up 1.3% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

There are too many aspects of Ocumension Therapeutics to cover in one brief article, but the key fundamentals for the company can all be found in one place – Ocumension Therapeutics' company page on Simply Wall St. We've also compiled a list of pertinent aspects you should further research:

1. Valuation: What is Ocumension Therapeutics worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Ocumension Therapeutics is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Ocumension Therapeutics’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.